<DOC>
	<DOC>NCT00136292</DOC>
	<brief_summary>The purpose of this study is to evaluate the pharmacokinetics of a single dose of daptomycin in patients aged 2-17 years old who have a suspected or proven gram-positive infection for which they are receiving standard antibiotic therapy. The tolerability of a single dose of daptomycin in these patients will also be assessed.</brief_summary>
	<brief_title>Study of Single Dose Daptomycin in Pediatric Patients With Gram-Positive Infection for Which They Are Receiving Standard Antibiotics</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Gram-Positive Bacterial Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<criteria>217 years old Suspected or diagnosed grampositive infection for which the patient is receiving standard antibiotic therapy Clinically stable with no evidence of hemodynamic instability in the 72 hour window prior to enrollment, and no history or evidence of renal or hepatic compromise, or clinically significant alterations in fluid/electrolyte homeostasis Creatinine clearance (CLcr) â‰¥ 80 ml/min/1.73 m2 as determined by the Schwartz equation Creatine phosphokinase (CPK) levels within normal limits Known allergy to daptomycin History of clinically significant cardiovascular, renal, hepatic, pulmonary (wellcontrolled asthma is acceptable), gastrointestinal, endocrine, hematologic, or autoimmune disease Pneumonia as sole grampositive infection Use of HMGCoA reductase inhibitors or other systemic antihyperlipidemic agents within 7 days prior to study drug administration and expected use through 3 days postdose Clinically significant abnormal laboratory test results (including electrocardiograms [ECGs]), as determined by Investigator Body mass index (BMI) that is outside of the 5th to 95th percentile for age History (personal or 1st degree relative) of clinically significant muscular disease, nervous system, seizure or psychiatric disorder Expected intramuscular (IM) injection within 3 days following dosing Expected surgical procedure(s) within 3 days following dosing Unexplained muscular weakness Rhabdomyolysis, myositis or septic shock</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Gram-Positive Infection</keyword>
</DOC>